Summary
Pneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with MTX. Its prevalence in rheumatoid arthritis (RA) has been estimated from several retrospective and prospective studies to range from 0.3% to 18%. On the other hand, MTX-induced pneumonitis seems to be very rare in psoriatic arthritis (PsA).
Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX-induced pneumonitis, giving a prevalence of 2.1% and 0.03%, respectively. Diagnosis was suggested by clinical history and radiographic findings, but the bronchoalveolar lavage plays an important role both in excluding infectious agents and in providing information for understanding the pathogenesis of lung injury. The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in MTX-induced pneumonitis. Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32: 671–6.
Hanrahan PS, Scrivens GA, Russel AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989; 28: 147–53.
Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM. Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clin Rheumatol 1990; 9: 333–41.
Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138–45.
Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Coblyn JS. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-months update. Arthritis Rheum 1992, 35: 129–37.
Salaffi F, Carotti M, Sartini A, Cervini C. A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 23–8.
Espinoza LR, Zakraoui L, Espinoza CG, Gutiérrez F, Jara LJ, Silveira LH, Cuéllar ML, Martinez-Osuna P. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872–7.
Sostman HD, Matthay RA, Putman CE, Smith GJW. Methotrexate-induced pneumonitis. Medicine 1976; 55: 371–88.
St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985; 145: 2035–8.
Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987; 16: 186–95.
Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14: 1164–71.
Gispen JG, Alarcón GS, Johnson JJ, Acton RT, Barger BO, Koopman WJ. Toxicity to methotrexate in rheumatoid arthritis. J Rheumatol 1987; 14: 74–9.
Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991; 20: 317–31.
Shergy WJ, Philips RM, Hunt RE, Huntsville AL. Pulmonary toxicity following chronic methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1992; 35: R17.
Cannon GW, Clegg DO, Samuelson CO Jr. Pulmonary toxicity during treatment of rheumatoid arthritis with methotrexate: prevalence, clinical features, treatment and follow-up. Arthritis Rheum 1984; 27: S26.
Boh LE, Schuna AA, Pitterle ME, Adams EM, Sundstrom WR. Lowdose weekly oral methotrexate therapy for inflammatory arthritis. Clin Pharm 1986; 5: 503–8.
Andersen PA, West SG, Nordstrom DM. Toxicity of chronic therapy with pulse methotrexate in rheumatoid arthritis: potential increased risk of infection. Arthritis Rheum 1987; 30: S60.
McKendry RJR, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20: 1850–6.
van der Veen MJ, Dekker JJ, Dinant HJ, Soesbergen RM, Bijlsma JWJ. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995; 22: 1766–8.
Buchdinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PFJ. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 639–44.
Bell MJ, Geddie WR, Gordon DA, Reynolds WJ. Pre-existing lung disease in patients with rheumatoid arthritis may predispose to methotrexate lung. Arthritis Rheum 1987; 29: S75.
Engelbrecht JA, Calhoon SL, Scherrer JJ. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 1983; 26: 1275–8.
Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992; 47: 628–33.
Carroll JG, Thomas R, Phatouros CC, Atchison MH, Leslie A-L, Cook NJ, D'Souza I. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21: 51–4.
Barrera P, Laan RFJM, van Riel PLCM, Dekhuijzen PNR, Boerbooms AM Th, Van de Putte LBA. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 43–49.
Hilliquin P, Renoux M, Perrot S, Puéchal X, Menkès CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996; 35: 441–5.
Maier WP, Roberto LP, Miller SM. Pneumonitis during low dose methotrexate therapy. Arch Intern Med 1986; 146: 602–3.
Anaya JM, Gutierrez M, Peray P, Jorgensen C, Sany J. Predictive value of pulmonary function tests in methotrexate induced pneumonitis in rheumatoid arthritis. Arthritis Rheum 1992; 35: S147.
Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1043–7.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3: 55–78.
Salaffi F, Subiaco S, Carotti M, Sartini A, Binci MC, Blasetti P, Novello, G, Cervini C. Bronchoalveolar lavage in primary Sjögren's syndrome. Eur J Intern Med 1995; 6: 109–16.
Ridley MG, Wolfe CS, Mathews JA. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988; 47: 784–8.
Israel CW, Wegener M, Adamek RJ, Bitsch T, Weber K, Ricken D. Severe pneumonitis as a complication of low-dose methotrexate therapy in psoriasis-associated polyarthritis. Dtsch Med Wochenschr 1995; 120: 603–8.
Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994; 107: 266–70.
Barrera P, van Ede AE, Laan RFJM, van Riel PLCM, Boerbooms AMTh, van de Putte LBA. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of five cases in a period of three months. Ann Rheum Dis 1994; 53: 479–80.
Green L, Schattner A, Berkenstadt H. Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of a case and review of the literature. J Rheumatol 1988; 15: 110–2.
Walden PAM, Mitchell-Heggs PF, Coppin C, Dent J, Bagshawe KD. Pleurisy and methotrexate treatment. Br Med J 1977; 2: 867.
Cottin V, Tébib J, Massonet B, Souquet P-J, Bernard J-P. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109: 933–8.
White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989; 139: 18–21.
Pourel J, Guillemin F, Fener P, Webanck L, Bene M-C, Delorme N. Delayed methotrexate pneumonitis in rheumatoid arthritis. J Rheumatol 1991; 18: 303–4.
Akoun GM, Mayaud CM, Touboul JL, Denis MF, Milleron BJ, Perrot JY. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease. Thorax 1987; 42: 652–5.
Akoun GM, Gauthier-Rahman S, Mayaud CM, Touboul JL, Denis MF. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 1987; 91: 96–9.
Leduc D, De Wuyst P, Lheureux P, Gevenois P-A, Jacobovitz D, Yernault J-C. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993; 104: 1620–3.
McKendry RJR, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case control study of 131 patients. Arch Intern Med 1989; 149: 685–9.
Elsasser S, Dalquen P, Soler M, Perruchoud AP. Methotrexate induced pneumonitis: appearance four weeks after discontinuation of treatment. Am Rev Respir Dis 1989; 140: 1089–92.
De Bandt M, Rat AC, Palazzo E, Kahn M-F. Delayed methotrexate pneumonitis. J Rheumatol 1991; 18: 1943.
Tsai J-J, Shin J-F, Chen C-H, Wang S-R. Methotrexate pneumonitis in bronchial asthma. Int Arch Allergy Immunol 1993; 100: 287–90.
Wollner A, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax 1991; 46: 205–7.
Lang B, Riegel W, Peters T, Peter H-H. Low dose methotrexate therapy for rheumatoid arthritis complicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol 1991; 18: 1257–9.
Clarysse AM, Cathey WJ, Cartwright GE, Wintrobe MM. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA 1969; 209: 1861–4.
Newman ED, Harrington TM. Fatal methotrexate pneumonitis in rheumatoid arthritis. Arthritis Rheum 1988; 31: 1585–6.
Cook NJ, Carroll GJ. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51: 272–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salaffi, F., Manganelli, P., Carotti, M. et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: Report of five cases and review of the literature. Clin Rheumatol 16, 296–304 (1997). https://doi.org/10.1007/BF02238967
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02238967